SCHEMBL4384381

SCHEMBL4384381

CCCCCCCC/C=C\CCCCCCCC(=O)NCCNC(=O)CCC(=O)O

nearest known ligand 0.85

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX2 P34913 2/20 0.85
KDM4E B2RXH2 1/20 0.78
FAAH O00519 3/20 0.78
CNR1 P21554 3/20 0.78
CNR2 P34972 2/20 0.78
KMT2A Q03164 3/20 0.71
MAPT P10636 3/20 0.71
MEN1 O00255 2/20 0.71
SLC6A5 Q9Y345 1/20 0.71
TERT O14746 3/20 0.69
PTPN1 P18031 3/20 0.69
PPARG P37231 3/20 0.69
PPARD Q03181 3/20 0.69
PPARA Q07869 3/20 0.69
BLM P54132 2/20 0.69
HSD17B10 Q99714 2/20 0.69
FABP4 P15090 2/20 0.69
GMNN O75496 1/20 0.69
USP2 O75604 1/20 0.69
LMNA P02545 1/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4384386 1.00 EPHX2 (0.85) EPHX2KDM4EFAAHCNR1CNR2
SCHEMBL10081341 0.97 EPHX2 (0.91) EPHX2KDM4EFAAHCNR1CNR2
SCHEMBL8339991 0.94 EPHX2 (0.85) EPHX2KDM4EFAAHCNR1CNR2
SCHEMBL27700201 0.94 EPHX2 (0.85) EPHX2KDM4EFAAHCNR1CNR2
SCHEMBL8339981 0.94 EPHX2 (0.85) EPHX2KDM4EFAAHCNR1CNR2
SCHEMBL3994209 0.94 FAAH (0.88) EPHX2KDM4EFAAHCNR1CNR2
SCHEMBL22926765 0.94 FAAH (0.88) EPHX2KDM4EFAAHCNR1CNR2
SCHEMBL10613896 0.94 FAAH (0.88) EPHX2KDM4EFAAHCNR1CNR2
SCHEMBL15298846 0.94 FAAH (0.88) EPHX2KDM4EFAAHCNR1CNR2
SCHEMBL25333433 0.93 EPHX2 (0.79) EPHX2KDM4EFAAHCNR1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120308646-A1 TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES ZHANG HESHENG (CN) 2012-12-06 US disclosed
US-20090325894-A1 TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES ZHANG HESHENG 2009-12-31 US disclosed
EP-2123283-A1 THE TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER EFFECT Tianjin Hemey Bio-Tech Co., Ltd. (CN) 2009-11-25 EP disclosed
CN-101225094-A Anthraquinones tetracyclic compound having anticancer activity TIANJIN HEMEI BIOTECHNOLOGY CO (CN) 2008-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325894-A1 TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES GLS2, GLS, VIP EPHX2 3917/4885KDM4E 4614/4885FAAH 1064/4885
US-20120308646-A1 TETRACYCLIC ANTHRAQUINONES POSSESSING ANTI-CANCER PROPERTIES ALAD, SLC27A2, ANTXR2 EPHX2 3342/4885KDM4E 3405/4885FAAH 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.